Detalles de la búsqueda
1.
Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.
Support Care Cancer
; 32(6): 353, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38748187
2.
Gene signature of circulating platelet-bound neutrophils is associated with poor prognosis in cancer patients.
Int J Cancer
; 151(1): 138-152, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35253899
3.
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.
Future Oncol
; 15(18): 2139-2149, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31185741
4.
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Onco Targets Ther
; 17: 439-448, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38836187
5.
Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.
Cancer Med
; 13(7): e7115, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38553950
6.
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Ther Adv Med Oncol
; 16: 17588359241236451, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38455711
7.
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
Nat Med
; 2024 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38898120
8.
Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
Clin Lung Cancer
; 24(1): 72-75, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36437214
9.
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.
Respir Med Res
; 83: 101004, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37037058
10.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37626173
11.
Occupational asbestos exposure and survival among lung cancer patients.
Lung Cancer
; 179: 107182, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001440
12.
Survival of bronchopulmonary cancers according to radon exposure.
Front Public Health
; 11: 1306455, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38328545
13.
Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.
Eur J Cancer
; 183: 38-48, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36801605
14.
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer.
J Thorac Oncol
; 18(10): 1408-1415, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37217096
15.
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.
BioDrugs
; 36(2): 137-151, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35147894
16.
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.
Front Oncol
; 12: 796832, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35251972
17.
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Cancer Treat Rev
; 103: 102335, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35033867
18.
Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.
Front Oncol
; 12: 852540, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223530
19.
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study.
Ther Adv Med Oncol
; 14: 17588359221099399, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35694190
20.
Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.
Eur J Cancer
; 169: 106-122, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550950